- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that Robert Saltmarsh, Vice President and Chief Financial Officer, will retire at the end of February 2008. Nick Venuto, currently the Executive Director of Finance, will become the Chief Financial Officer upon Mr. Saltmarsh's retirement. Mr. Saltmarsh will continue to consult with Nanogen, as needed, through the end of 2008.
We thank Rob for his outstanding service as our CFO and for the significant contributions he made to Nanogen during his tenure," said Howard Birndorf, Chairman and CEO. "As our executive director of finance, Nick Venuto has been responsible for financial operations and reporting at Nanogen for the last four years. Nick is also a CPA and has experience in public accounting as well as in industry. We are pleased to have someone of Nick's experience and capabilities step into the CFO role."
About Nanogen, Inc.
Nanogenís advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents and kits based on the Companyís proprietary probe technology branded as MGB Alertģ and Q-PCR Alert, and a line of rapid point-of-care diagnostic tests used in urgent care settings to aid in the diagnosis of heart failure conditions. Nanogenís ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including those relating to the need for additional financing, reduction of expenses after restructuring activity, anticipated cash flow and profit, delisting from the NASDAQ Global Market, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Risk Factors" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
President & COO
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Yale researchersí technology turns wasted heat into power June 27th, 2016
FEI Launches Helios G4 DualBeam Series for Materials Science: The Helios G4 DualBeam Series features new capabilities to enable scientists and engineers to answer the most demanding and challenging scientific questions June 27th, 2016